Initiation of Once Weekly (QW) Insulin Efsitora alfa (efsitora) in 3 Patient Populations
in Phase 2 Studies Using a One-time Loading Dose (LD) Minimizes Transient Hyperglycemia
and is not Associated with Excess Hypoglycemia Risk vs Degludec
Authors
Juliana Bue-Valleskey
1
Eli Lilly and Company, Insulins and Devices, Indianapolis, IN, United States
Christof Kazda
2
Eli Lilly and Company, Clinical Research – Incretins & Incretin Combinations, Indianapolis,
IN, United States
Qianyi Zhang
3
Eli Lilly and Company, Diabetes and Obesity, Indianapolis, IN, United States
Axel Haupt
4
Eli Lilly and Company, Diabetes & Metabolic Research, Indianapolis, IN, United States
Dominik Dahl
5
Gemeinschaftspraxis für Innere Medizin und Diabetologie, Diabetologie, Hamburg, Germany,
Germany
Juan Frias
6
Velocity Clinical Research, Medical Director and Principal Investigator , Los Angeles,
CA, United States
Andreas Liebl
7
m&i-Fachklinik Bad Heilbrunn, Zentrum für Diabetes und Stoffwechselerkrankungen, Bad
Heilbrunn, Germany
